Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hay

Showing results (571-580 of 655) with videos related to

Pageof 66
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 7, 2017
Gynecologic Oncologist Views Influencing Referral to Outpatient Specialty Palliative CareCasey M Hay, Carolyn Lefkowits, Megan Crowley-Matoka, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 23, 2020
Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical companyCharles R M Hay, Midori Shima, Michael Makris, et al.
Journal of Thrombosis and Haemostasis : JTH|August 29, 2018
Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophiliaR A Gruppo, D Malan, J Kapocsi, et al.
Research and Practice in Thrombosis and Haemostasis|October 6, 2025
Emicizumab utilization, safety, and outcomes in people with severe hemophilia and no inhibitors: 3-year follow-up. A report from the UK Haemophilia Centre Doctors' OrganisationCaroline Wall, Hua Xiang, Ben Palmer, et al.
Clinical and Experimental Immunology|August 1, 1991
An abnormal T cell repertoire in hypergammaglobulinaemic primary Sjögren's syndromeR A Kay, E M Hay, P A Dyer, et al.
Rheumatology (Oxford, England)|October 18, 2000
Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?S M Griffith, J Fisher, S Clarke, et al.
Blood|April 21, 2007
Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIVSarah C Darby, Sau Wan Kan, Rosemary J Spooner, et al.
Journal of Thrombosis and Haemostasis : JTH|December 17, 2020
Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting databaseSteven W Pipe, Rebecca Kruse-Jarres, Johnny N Mahlangu, et al.
Sports Health|September 12, 2023
Serum Cartilage Oligomeric Matrix Protein Concentration Increases More After Running Than Swimming for Older PeopleAlexandra M Hay, Madison J Rhoades, Stephanie Bangerter, et al.
BMJ Open|March 12, 2018
Using an internet intervention to support self-management of low back pain in primary care: findings from a randomised controlled feasibility trial (SupportBack)Adam W A Geraghty, Rosie Stanford, Beth Stuart, et al.
Pageof 66

Showing results (571-580 of 655) with videos related to

Sort By:
Pageof 66
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 7, 2017
Gynecologic Oncologist Views Influencing Referral to Outpatient Specialty Palliative CareCasey M Hay, Carolyn Lefkowits, Megan Crowley-Matoka, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 23, 2020
Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical companyCharles R M Hay, Midori Shima, Michael Makris, et al.
Journal of Thrombosis and Haemostasis : JTH|August 29, 2018
Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophiliaR A Gruppo, D Malan, J Kapocsi, et al.
Research and Practice in Thrombosis and Haemostasis|October 6, 2025
Emicizumab utilization, safety, and outcomes in people with severe hemophilia and no inhibitors: 3-year follow-up. A report from the UK Haemophilia Centre Doctors' OrganisationCaroline Wall, Hua Xiang, Ben Palmer, et al.
Clinical and Experimental Immunology|August 1, 1991
An abnormal T cell repertoire in hypergammaglobulinaemic primary Sjögren's syndromeR A Kay, E M Hay, P A Dyer, et al.
Rheumatology (Oxford, England)|October 18, 2000
Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?S M Griffith, J Fisher, S Clarke, et al.
Blood|April 21, 2007
Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIVSarah C Darby, Sau Wan Kan, Rosemary J Spooner, et al.
Journal of Thrombosis and Haemostasis : JTH|December 17, 2020
Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting databaseSteven W Pipe, Rebecca Kruse-Jarres, Johnny N Mahlangu, et al.
Sports Health|September 12, 2023
Serum Cartilage Oligomeric Matrix Protein Concentration Increases More After Running Than Swimming for Older PeopleAlexandra M Hay, Madison J Rhoades, Stephanie Bangerter, et al.
BMJ Open|March 12, 2018
Using an internet intervention to support self-management of low back pain in primary care: findings from a randomised controlled feasibility trial (SupportBack)Adam W A Geraghty, Rosie Stanford, Beth Stuart, et al.
Pageof 66